Centeon is the name of the 50/50 joint venture set up by Franco-American pharmaceutical company Rhone-Poulenc Rorer and German firm Hoechst, in a move to create the first global plasma protein therapies company.
The new $1.2 billion-a-year-sales firm is the result of the merging of the existing blood plasma divisions of the two parent companies, and is based in King of Prussia, Pennsylvania. Hoechst has contributed all the assets of the plasma protein division of Behringwerke AG of Germany, and R-PR has contributed all the plasma protein-related assets of its subsidiary Armour of the USA, as was agreed last year (Marketletter March 20, 1995). Centeon will be run by independent management, with its own board.
"Our strategy is clear," commented John Sedor, chief executive of Centeon. "Centeon will invest in research and development to lead the plasma protein industry in accelerating the availability of new products from human plasma and through biotechnology."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze